

Conatus Pharmaceuticals Inc.  
Form 8-K  
June 25, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 21, 2018**

**CONATUS PHARMACEUTICALS INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**

**001-36003**

**20-3183915**

(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
---	-----------------------------	--

16745 West Bernardo Drive, Suite 200

92127

San Diego, CA

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (858) 376-2600

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

..

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07**

**Submission of Matters to a Vote of Security Holders.**

Conatus Pharmaceuticals Inc. (the “Company”) held its annual meeting of stockholders on June 21, 2018. The following is a brief description of each matter voted upon at the meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.

1. The election of two nominees to serve as Class II directors for a three-year term to expire at the 2021 annual meeting of stockholders. The following two Class II directors were re-elected by the votes indicated:

	For	Withheld	Broker Non-Votes
Daniel L. Kisner, M.D.	13,202,047	400,268	13,089,943
James Scopa	13,012,623	589,692	13,089,943

2. The ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018. The selection was ratified by the votes indicated:

For	Against	Abstain	Broker Non-Votes
26,544,463	78,841	68,954	0

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 25, 2018      CONATUS PHARMACEUTICALS INC.

By:            /s/ Steven J. Mento, Ph.D.  
Name:        Steven J. Mento, Ph.D.  
Title:        President and Chief Executive  
                 Officer